243 related articles for article (PubMed ID: 24440112)
1. Revaccination with 7-valent pneumococcal conjugate vaccine elicits better serologic response than 23-valent pneumococcal polysaccharide vaccine in HIV-infected adult patients who have undergone primary vaccination with 23-valent pneumococcal polysaccharide vaccine in the era of combination antiretroviral therapy.
Lu CL; Chang SY; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Hung CC
Vaccine; 2014 Feb; 32(9):1031-5. PubMed ID: 24440112
[TBL] [Abstract][Full Text] [Related]
2. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.
Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Su YC; Chang SF; Chang SY; Chang SC
Hum Vaccin Immunother; 2013 Feb; 9(2):398-404. PubMed ID: 23291936
[TBL] [Abstract][Full Text] [Related]
3. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.
Lee KY; Tsai MS; Kuo KC; Tsai JC; Sun HY; Cheng AC; Chang SY; Lee CH; Hung CC
Hum Vaccin Immunother; 2014; 10(12):3700-10. PubMed ID: 25483681
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil.
Ho YL; Brandão AP; de Cunto Brandileone MC; Lopes MH
Vaccine; 2013 Aug; 31(37):4047-53. PubMed ID: 23684823
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults.
Crum-Cianflone NF; Huppler Hullsiek K; Roediger M; Ganesan A; Patel S; Landrum ML; Weintrob A; Agan BK; Medina S; Rahkola J; Hale BR; Janoff EN;
J Infect Dis; 2010 Oct; 202(7):1114-25. PubMed ID: 20795819
[TBL] [Abstract][Full Text] [Related]
6. Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy.
Cheng A; Chang SY; Tsai MS; Su YC; Liu WC; Sun HY; Hung CC
J Int AIDS Soc; 2016; 19(1):20631. PubMed ID: 26829360
[TBL] [Abstract][Full Text] [Related]
7. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
Stanford E; Print F; Falconer M; Lamden K; Ghebrehewet S; Phin N; Baxter D; Helbert M; McCann R; Andrews N; Balmer P; Borrow R; Kaczmarski E
Hum Vaccin; 2009 Feb; 5(2):85-91. PubMed ID: 18758242
[TBL] [Abstract][Full Text] [Related]
8. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.
Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Hsiao CF; Tseng YT; Su YC; Chang SF; Chang SY; Chang SC
Vaccine; 2012 May; 30(24):3526-33. PubMed ID: 22484349
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age.
Miernyk KM; Butler JC; Bulkow LR; Singleton RJ; Hennessy TW; Dentinger CM; Peters HV; Knutsen B; Hickel J; Parkinson AJ
Clin Infect Dis; 2009 Jul; 49(2):241-8. PubMed ID: 19522655
[TBL] [Abstract][Full Text] [Related]
10. Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia.
Lindström V; Aittoniemi J; Salmenniemi U; Käyhty H; Huhtala H; Sinisalo M
Hum Vaccin Immunother; 2019; 15(12):2910-2913. PubMed ID: 31216225
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
[TBL] [Abstract][Full Text] [Related]
12. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
[TBL] [Abstract][Full Text] [Related]
13. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
Glesby MJ; Watson W; Brinson C; Greenberg RN; Lalezari JP; Skiest D; Sundaraiyer V; Natuk R; Gurtman A; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
J Infect Dis; 2015 Jul; 212(1):18-27. PubMed ID: 25395187
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and Immunological Memory Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults.
Farmaki PF; Chini MC; Mangafas NM; Tzanoudaki MT; Piperi CP; Lazanas MZ; Spoulou VS
J Infect Dis; 2018 Jun; 218(1):26-34. PubMed ID: 29722823
[TBL] [Abstract][Full Text] [Related]
17. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine.
Smets F; Bourgois A; Vermylen C; Brichard B; Slacmuylders P; Leyman S; Sokal E
Vaccine; 2007 Jul; 25(29):5278-82. PubMed ID: 17576024
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.
Lombardi F; Belmonti S; Fabbiani M; Morandi M; Rossetti B; Tordini G; Cauda R; De Luca A; Di Giambenedetto S; Montagnani F
PLoS One; 2016; 11(6):e0156523. PubMed ID: 27258647
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation.
Cordonnier C; Labopin M; Chesnel V; Ribaud P; De La Camara R; Martino R; Ullmann AJ; Parkkali T; Locasciulli A; Yakouben K; Pauksens K; Einsele H; Niederwieser D; Apperley J; Ljungman P;
Clin Infect Dis; 2009 May; 48(10):1392-401. PubMed ID: 19368505
[TBL] [Abstract][Full Text] [Related]
20. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial.
Cordonnier C; Labopin M; Chesnel V; Ribaud P; Camara Rde L; Martino R; Ullmann AJ; Parkkali T; Locasciulli A; Yakouben K; Pauksens K; Bonnet E; Einsele H; Niederwieser D; Apperley J; Ljungman P
Vaccine; 2010 Mar; 28(15):2730-4. PubMed ID: 20117269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]